JAK1 and Alzheimer disease: Approved in January 2022 (14 January 2022), abrocitinib (brand name Cibinqo®) is a selective Janus kinase 1 (JAK1) inhibitor effective and safe for the treatment of atopic dermatitis (AD), with good oral bioavailability as well as lack of immunogenicity, addressing some of the limitations of biologic drugs currently available.